In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are 12 new oncology products developed to treat hematological malignancies that, if successful at the regulators, are due to be launched for the first time next year.

The Danish group put the 5-HT6 antagonist on the shelf after three failed late-stage trials but Denovo believes that idalopirdine could still work for a subset of Alzheimer's patients.

Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.

Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.